🇺🇸 FDA
Patent

US 11596690

Stabilized formulations containing anti-IL-33 antibodies

granted A61KA61K39/39591A61K47/12

Quick answer

US patent 11596690 (Stabilized formulations containing anti-IL-33 antibodies) held by REGENERON PHARMACEUTICALS, INC. expires Mon Mar 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
REGENERON PHARMACEUTICALS, INC.
Grant date
Tue Mar 07 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
29
CPC classes
A61K, A61K39/39591, A61K47/12, A61K47/18, A61K47/183